CARsgen Therapeutics Holdings (HKSE:02171) ROCE % : -31.18% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is CARsgen Therapeutics Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. CARsgen Therapeutics Holdings's annualized ROCE % for the quarter that ended in Dec. 2023 was -31.18%.

CARsgen Therapeutics Holdings ROCE % Historical Data

The historical data trend for CARsgen Therapeutics Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARsgen Therapeutics Holdings ROCE % Chart

CARsgen Therapeutics Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-461.07

-225.59

-29.14

-31.56

CARsgen Therapeutics Holdings Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial				-20.42	-23.81	-36.02	-32.43	-31.18

CARsgen Therapeutics Holdings ROCE % Calculation

CARsgen Therapeutics Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-812.375	/	( ( (3085.281 - 190.963)	+	(2468.893 - 214.618) )	/ 2 )
	=	-812.375	/	( (2894.318	+	2254.275)	/ 2 )
	=	-812.375	/	2574.2965
	=	-31.56 %

CARsgen Therapeutics Holdings's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-745.502	/	( ( (2893.003 - 365.112)	+	(2468.893 - 214.618) )	/ 2 )
	=	-745.502	/	( ( 2527.891	+	2254.275 )	/ 2 )
	=	-745.502	/	2391.083
	=	-31.18 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

CARsgen Therapeutics Holdings (HKSE:02171) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

CARsgen Therapeutics Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of CARsgen Therapeutics Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

CARsgen Therapeutics Holdings (HKSE:02171) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARsgen Therapeutics Holdings Ltd (HKSE:02171) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CRTHF:USA

Address

No. 388 Yindu Road, Building 12, CMC Preparation Center, Xuhui District, Shanghai, CHN

Website

https://www.carsgen.com

CARsgen Therapeutics Holdings Ltd is a global clinical-stage biopharmaceutical company discovering, researching and developing cell therapies in the People's Republic of China and the United States of America.

Executives

Guo Bingsen	2401 A concert party to an agreement to buy shares
Guo Huaqing	2101 Beneficial owner
Li Zonghai	2401 A concert party to an agreement to buy shares
Wang Huamao	2401 A concert party to an agreement to buy shares
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Gic Private Limited	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Yang Zhi	2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd	2201 Interest of corporation controlled by you
Bvcf Realization Fund, L.p.	2201 Interest of corporation controlled by you
Bvcf Realization Fund Gp, Ltd.	2201 Interest of corporation controlled by you
Zhejiang Jolly Healthcare Investment Management Limited	2201 Interest of corporation controlled by you
Applied Biomaterial Ltd.	2201 Interest of corporation controlled by you
Zhejiang Jolly Pharmaceutical Co., Ltd.	2201 Interest of corporation controlled by you
Zhejiang Zuoli Innovation Medical Investment Management Co., Ltd.	2101 Beneficial owner

CARsgen Therapeutics Holdings (HKSE:02171) Headlines

No Headlines